Proteomic aging clocks go to trial
Peer-reviewed commentary; per secondary coverage the trial revealed more about clock behaviour than drug effect. Intervention, n and effect sizes unverified.
Evidence
4/10
Emerging Evidence
Sample
—
subjects
Duration
—
study period
Journal
Nature Biotechnology
Oct 2026
Full Abstract
Commentary on deployment of six proteomic aging clocks as readouts in a randomized intervention study.
Key Findings
- 01
Six proteomic clocks used together as trial readouts
- 02
Comparison exposes convergence/divergence and reliability issues of the clocks
- 03
No established surrogate-endpoint standing for proteomic age scores
Structured Methods
- Study Design
- Review
- Sample Size
- Not reported
- Study Duration
- Not reported
- Methodology
- Commentary
- Limitations
- Commentary, not primary data; trial details taken from secondary coverage.
Citations & References
Robertson NA, Chandra T (2026). Proteomic aging clocks go to trial. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03361-4
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation